Medical and surgical treatment of neovascular glaucoma

International Ophthalmology Clinics

Volumn 51, Issue 3, 2011, Pages 27-36

  Olmos, Lisa C ^a   Lee, Richard K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CARBONATE DEHYDRATASE INHIBITOR; CYCLOPLEGIC AGENT; FLUOROURACIL; MITOMYCIN C; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; STEROID;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ARTICLE; CENTRAL RETINA VEIN OCCLUSION; CORNEA EDEMA; CYCLOPHOTOCOAGULATION; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG TOLERANCE; EYE INFLAMMATION; EYE INJURY; EYE PAIN; FOLLOW UP; GLAUCOMA DRAINAGE IMPLANT; GLAUCOMA SURGERY; HUMAN; HYPHEMA; INTRAOCULAR HEMORRHAGE; INTRAOCULAR HYPERTENSION; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE; IRIS; LASER COAGULATION; NEOVASCULAR GLAUCOMA; OPTIC NERVE; OPTIC NERVE INJURY; OPTIC NERVE LESION; OUTCOME ASSESSMENT; PANRETINAL PHOTOCOAGULATION; PARACENTESIS; PARS PLANA VITRECTOMY; PRIORITY JOURNAL; PROSTHESIS FAILURE; RECURRENT DISEASE; RETINA ISCHEMIA; RETINA NEOVASCULARIZATION; RISK FACTOR; TRABECULECTOMY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIHYPERTENSIVE AGENTS; GLAUCOMA DRAINAGE IMPLANTS; GLAUCOMA, NEOVASCULAR; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; ISCHEMIA; LIGHT COAGULATION; RETINAL VESSELS; TRABECULECTOMY;

EID: 79958171044     PISSN: 00208167     EISSN: 15369617     Source Type: Journal    
DOI: 10.1097/IIO.0b013e31821e5960     Document Type: Article

References (22)

1. Weiss DI, Shaffer RN, Nehrenberg TR. Neovascular glaucoma complicating carotid-cavernous fistula. Arch Ophthalmol. 1963;69:304. Lippincott Williams and Wilkins; 2005 328-341
2. Allingham RR, Damji K, Freedman S, et al. eds. Glaucomas Associated with Disorders of the Retina, Vitreous, and Choroid. In: Allingham RR, Damji K, Freedman S, et al. Shields' Textbook of Glaucoma. ed 5. Philadelphia: Lippincott Williams and Wilkins; 2005:328-341.
3. MoraczewskiAL, Lee RK, Palmberg PF, et al. Outcomes oftreatment ofneovascular glaucoma with intravitreal bevacizumab. Br J Ophthalmol. 2009;93:589-593.
4. Wakabayashi T, Oshima Y, Sakaguchi H, et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal disease in 41 consecutive cases. Ophthalmology. 2008;115:1571-1580.
5. DavidorfFH, MouserJG, Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina. 2006;26:354-356. (Pubitemid 44318196)
6. Iliev ME, Domig D, Wolf-Schnurrbursch U, et al. Intravitreal bevacizumab (Avastin) in the treatment ofneovascular glaucoma. Am J Ophthalmol. 2006;142:1054-1056. (Pubitemid 44853889)
7. Kahook MY, Schuman JS, Noecker RJ. Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging. 2006;37:144-146.
8. Mason JO III, Albert MAJr, Mays A, et al. Regression ofneovascular iris vessels by intravitreal injection ofbevacizumab. Retina. 2006;26:839-841. (Pubitemid 44386115)
9. Paula JS, Jorge R, Costa RA, et al. Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma. Acta Ophthalmol Scand. 2006;84:556-557. (Pubitemid 44102857)
10. Gheith ME, Siam GA, de Barros DS, et al. Role of intravitreal bevacizumab in neovascular glaucoma.J Ocul Pharmacol Ther. 2007;23:487-491. (Pubitemid 350202480)
11. Chilov MN, Grigg JR, Playfair TJ. Bevacizumab (Avastin) for the treatment of neovascular glaucoma. Clin Exp Ophthalmol. 2007;35:494-496. (Pubitemid 47162770)
12. Yazdani S, Hendi K, Pakravan M, et al. Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial.J Glaucoma. 2009;18:632-637.
13. Tsai JC, Feuer WJ, Parrish RK II, et al. 5-Fluorouracil filtering surgery and neovascular glaucoma. Long-term follow-up of the original pilot study. Ophthalmology. 1995;102:887-892.
14. Takihara Y, Inatani M, Fukushima M, et al. Trabeculectomy with mitomycin C for neovascular glaucoma: prognostic factors for surgical failure. Am J Ophthalmol. 2009;147:912-918.
15. Park UC, Park KH, Kim DM, et al. Ahmed Glaucoma Valve Implantation for Neovascular Glaucoma after Vitrectomy for Proliferative Diabetic Retinopathy. J Glaucoma. 2010. (Epub ahead of print).
16. Leszczynski R, Domanksi R, Forminksa-Kapuscik M, et al. Contact transscleral cyclophotocoagulation in the treatment of neovascular glaucoma: a five-year follow-up. Med Sci Monit. 2009;15:BR84-BR87.
17. Pokroy R, Greenwald Y, Pollack A, et al. Visual loss after transscleral diode laser cyclophotocoagulation for primary open-angle and neovascular glaucoma. Ophthalmic SurgLasers Imaging. 2008;39:22-29. (Pubitemid 351311093)
18. Saito Y, Higashide T, Takeda H, et al. Beneficial effects ofpreoperative intravitreal bevacizumab on trabeculectomy outcomes in neovascular glaucoma. Acta Ophthalmo-logica. 2010;88:96-102.
19. Takihara Y, Inatani M, Kawaji T, et al. Combined Intravitreal Bevacizumab and Trabeculectomy with Mitomycin C Versus Trabeculectomy With Mitomycin C Alone for Neovascular Glaucoma. J Glaucoma. 2010. (Epub ahead of print).
20. Eid TM, Radwan A, El-Manawy W, et al. Intravtireal bevacizumab and aqueous shunting surgery for neovascular glaucoma: safety and efficacy. Can J Ophthal. 2009; 44:451-456.
21. Ciftci S, Sakalar YB, Unlu K, et al. Intravitreal bevacizumab combined with panretinal photocoagulation in the treatment of open angle neovascular glaucoma. Eur J Ophthal. 2009;19:1028-1033.
22. Ehlers JP, Spirn MJ, Lam A, et al. Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma. Retina. 2008;28:696-702. (Pubitemid 351655121)